Design of the RHEMEDY Study: A Phase 2/3 Safety, Efficacy and Pharmacokinetics Study of CSL889 in Adults and Adolescents with Sickle Cell Disease During Vaso-Occlusive Crisis

Presenting Author(s)

• 

  Paul M. Shore, MD, MS

  Clinical Program Director, Hematology
  CSL Behring
  Drexel University College of Medicine
  King of Prussia, Pennsylvania, United States

  Slides

Co-Author(s)

• VG

  Victor R. Gordeuk, M.D.

  Interim Director of the Hematology-Oncology Fellowship Program
  University of Illinois at Chicago
  Chicago, Illinois, United States
• DB

  David Brousseau, M.D., M.S.

  Robert L Brent Professor and Chair, Department of Pediatrics
  Nemours Children's Health and Sidney Kimmel Medical College at Thomas Jefferson University, Delaware, United States
• CK

  Christian Kassasseya, MD

  Science Researcher, Team Pirenne, Institut Mondor de Recherche Biomédicale
  Henri Mondor University Hospital, Ile-de-France, France
• NA

  Nicole Avalos, PhD

  Global Safety Lead
  CSL Behring, Bern, Switzerland
• KJ

  Kerstin Jung, n/a

  Senior Global Trial Leader
  CSL Innovation GmbH, Hessen, Germany
• JM

  Jeannine S. McCune, PharmD, PhD

  Director, Clinical Pharmacology & Pharmacometrics
  CSL Behring, Pennsylvania, United States
• 

  Francine Wilson, MS

  Principal Clinical Scientist
  CSL Behring
  King of Prussa, Pennsylvania, United States
• HZ

  Heng Zou, PhD

  Biostatistician
  CSL Behring, Pennsylvania, United States
• 

  Paula Tanabe, PHD, MPH, MSN, RN, FAEN, FAAN

  Laurel B. Chadwick Distinguished Professor (Tenured)
  Duke University School of Nursing
  Duke University School of Nursing
  Durham, North Carolina, United States
• BB

  Bart J. Biemond, MD, PhD

  Professor, Medical head Hemoglobinopathy Expertise Center
  Amsterdam University Medical Centers
  Amsterdam, Noord-Holland, Netherlands